# David T Dexter

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 35 papers | 3,737 citations | 25 h-index | 39 g-index |
| 39 ext. papers | 4,235 ext. citations | 6.2 avg, IF | 5.25 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 35 | Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. *Annals of Neurology*, **1994**, 36, 348-55 | 9.4 | 918 |
| 34 | Parkinson disease: from pathology to molecular disease mechanisms. *Free Radical Biology and Medicine*, **2013**, 62, 132-144 | 7.8 | 417 |
| 33 | Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. *Movement Disorders*, **1994**, 9, 92-7 | 7 | 367 |
| 32 | Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. *Free Radical Research*, **2005**, 39, 1119-25 | 4 | 317 |
| 31 | Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. *Journal of Neuroinflammation*, **2005**, 2, 14 | 10.1 | 254 |
| 30 | Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. *Scientific Reports*, **2017**, 7, 1398 | 4.9 | 178 |
| 29 | Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. *NeuroReport*, **2001**, 12, 3871-5 | 1.7 | 159 |
| 28 | Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. *Journal of Neural Transmission*, **2011**, 118, 223-31 | 4.3 | 99 |
| 27 | Neurodegenerative diseases and therapeutic strategies using iron chelators. *Journal of Trace Elements in Medicine and Biology*, **2015**, 31, 267-73 | 4.1 | 86 |
| 26 | Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study. *PLoS Medicine*, **2015**, 12, e1001854 | 11.6 | 76 |
| 25 | Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of HS-synthesizing enzymes. *Scientific Reports*, **2017**, 7, 42871 | 4.9 | 75 |
| 24 | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. *Movement Disorders*, **2001**, 16, 424-34 | 7 | 70 |
| 23 | Iron as a therapeutic target for Parkinson's disease. *Movement Disorders*, **2018**, 33, 568-574 | 7 | 65 |
| 22 | Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. *Biochemical Pharmacology*, **1995**, 49, 1821-6 | 6 | 61 |
| 21 | Multibranched Gold Nanoparticles with Intrinsic LAT-1 Targeting Capabilities for Selective Photothermal Therapy of Breast Cancer. *ACS Applied Materials & Interfaces*, **2017**, 9, 39259-39270 | 9.5 | 59 |
| 20 | Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson's disease. *Journal of the American College of Nutrition*, **2007**, 26, 341-9 | 3.5 | 58 |
| 19 | Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease. *Neurobiology of Disease*, **2015**, 74, 392-405 | 7.5 | 57 |

| | | | |
|---|---|---|---|
| 18 | Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. *NeuroReport* , **2003**, 14, 47-50 | 1.7 | 56 |
| 17 | Pathological histone acetylation in Parkinsonʼs disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. *Neuroscience Letters*, **2018**, 666, 48-57 | 3.3 | 53 |
| 16 | Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. *Journal of Neurochemistry*, **2007**, 100, 678-92 | 6 | 48 |
| 15 | L-DOPA functionalized, multi-branched gold nanoparticles as brain-targeted nano-vehicles. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 15, 1-11 | 6 | 40 |
| 14 | Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinsonʼs is associated with histone acetylation and up-regulation of neurotrophic factors. *British Journal of Pharmacology*, **2015**, 172, 4200-15 | 8.6 | 37 |
| 13 | Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinsonʼs disease. *Molecular Neurodegeneration*, **2015**, 10, 47 | 19 | 36 |
| 12 | The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinsonʼs disease. *Journal of Neurochemistry*, **2019**, 148, 136-156 | 6 | 30 |
| 11 | High resolution and dynamic imaging of biopersistence and bioreactivity of extra and intracellular MWNTs exposed to microglial cells. *Biomaterials*, **2015**, 70, 57-70 | 15.6 | 27 |
| 10 | The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival. *Theranostics*, **2018**, 8, 3977-3990 | 12.1 | 25 |
| 9 | Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat. *Biochemical Pharmacology*, **1999**, 58, 151-5 | 6 | 21 |
| 8 | Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate. *Neuroscience Letters*, **2016**, 614, 16-23 | 3.3 | 13 |
| 7 | Brain iron metabolism and its perturbation in neurological diseases. *Monatshefte Fü Chemie*, **2011**, 142, 341-355 | 1.4 | 10 |
| 6 | Iron and inflammation: in vivo and post-mortem studies in Parkinsonʼs disease. *Journal of Neural Transmission*, **2021**, 128, 15-25 | 4.3 | 9 |
| 5 | DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. *Neurotherapeutics*, **2020**, 17, 1120-1141 | 6.4 | 7 |
| 4 | Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinsonʼs disease. *Archives of Toxicology*, **2020**, 94, 813-831 | 5.8 | 4 |
| 3 | Is Chelation Therapy a Potential Treatment for Parkinsonʼs Disease?. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 4 |
| 2 | Data Sharing Goals for Nonprofit Funders of Clinical Trials. *Journal of Participatory Medicine*, **2021**, 13, e23011 | 1.4 | 0 |
| 1 | Electron Microscopic Characterization of Functionalized Multi-Walled Carbon Nanotubes and Their Interactions with the Blood Brain Barrier. *Microscopy and Microanalysis*, **2014**, 20, 1744-1745 | 0.5 | |